AmoyDx® Master Panel

The AmoyDx Master Panel facilitates the concurrent detection of both DNA and RNA biomarkers. On the DNA level, it encompasses 571 genes, encompassing biomarkers associated with approved targeted therapies, as well as those recommended by guidelines/consensus or under investigation in clinical trials. In addition to SNV/indel, fusion, and CNV analysis, the Master Panel also evaluates complex signatures such as HRD, MSI, and TMB. On the RNA level, it surveys over 2000 genes, detecting fusions and alternative splicing while analyzing levels of genes implicated in cancer pathways. Furthermore, it enables the assessment of select immunotherapy biomarkers like GEP and TME.